Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications DOI Creative Commons
Farah Abdelhameed, A.I. Mustafa, Chris Kite

et al.

Livers, Journal Year: 2025, Volume and Issue: 5(1), P. 11 - 11

Published: March 4, 2025

Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic (MASLD), is the most common cause of chronic worldwide. Characterized by excessive hepatic fat accumulation, this encompasses a spectrum from simple steatosis to more severe forms, including steatohepatitis, fibrosis, and cirrhosis. Emerging evidence highlights pivotal role gut dysbiosis in pathogenesis MASLD. Dysbiosis disrupts gut–liver axis, an intricate communication network that regulates metabolic, immune, barrier functions. Alterations microbiota composition, increased permeability, translocation pro-inflammatory metabolites/factors have been shown trigger inflammatory fibrotic cascades, exacerbating inflammation injury. Recent studies identified microbiome signatures associated with MASLD, offering promise non-invasive diagnostic biomarkers paving way for new potential therapeutic strategies targeting dysbiosis. This review explores crucial MASLD need further targeted research field validate microbial optimize strategies. Comprehensive understanding axis may enable innovative approaches, transforming clinical management

Language: Английский

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications DOI Creative Commons
Farah Abdelhameed, A.I. Mustafa, Chris Kite

et al.

Livers, Journal Year: 2025, Volume and Issue: 5(1), P. 11 - 11

Published: March 4, 2025

Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic (MASLD), is the most common cause of chronic worldwide. Characterized by excessive hepatic fat accumulation, this encompasses a spectrum from simple steatosis to more severe forms, including steatohepatitis, fibrosis, and cirrhosis. Emerging evidence highlights pivotal role gut dysbiosis in pathogenesis MASLD. Dysbiosis disrupts gut–liver axis, an intricate communication network that regulates metabolic, immune, barrier functions. Alterations microbiota composition, increased permeability, translocation pro-inflammatory metabolites/factors have been shown trigger inflammatory fibrotic cascades, exacerbating inflammation injury. Recent studies identified microbiome signatures associated with MASLD, offering promise non-invasive diagnostic biomarkers paving way for new potential therapeutic strategies targeting dysbiosis. This review explores crucial MASLD need further targeted research field validate microbial optimize strategies. Comprehensive understanding axis may enable innovative approaches, transforming clinical management

Language: Английский

Citations

0